Non-invasive intranasal insulin-like growth factor-I reduces infarct volume and improves neurologic function in rats following middle cerebral artery occlusion

Insulin-like growth factor-I (IGF-I) has been proposed as a treatment for stroke. However, it does not efficiently cross the blood-brain barrier (BBB). Intracerebroventricular injection of IGF-I has been shown to offer protection against cerebral ischemic damage in rats although this invasive method of administration may not be practical in humans. Non-invasive intranasal (IN) delivery of IGF-I to the brain is a promising alternative. We have assessed the therapeutic effect of IN IGF-I in rats following middle cerebral artery occlusion (MCAO). Treatment was initiated 10 min after the onset of MCAO and then again 24 and 48 h later. Intranasal dosing of 75 microg IGF-1 (225 microg total IGF-I over 48 h) significantly reduced corrected infarct volumes by 60% vs. control (P<0.01) and hemispheric swelling by 45.6% vs. control (P<0.05). Neurologic function, assessed by the postural reflex, flexor response and adhesive tape tests, was also improved by IN IGF-I as compared to control. Our study indicates IN delivery of IGF-1 holds significant promise as a non-invasive and efficacious method of bypassing the BBB for the treatment of stroke.

[1]  S. Finger,et al.  Sensorimotor cortical lesion effects and treatment with nimodipine , 1990, Physiology & Behavior.

[2]  M. Mattson,et al.  Growth factors protect neurons against excitotoxic/ischemic damage by stabilizing calcium homeostasis. , 1993, Stroke.

[3]  M. Gunning,et al.  The Effects of IGF-1 Treatment after Hypoxic-Ischemic Brain Injury in Adult Rats , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[4]  N. Ling,et al.  Displacement of insulin-like growth factors from their binding proteins as a potential treatment for stroke. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[5]  N. Lobaugh,et al.  Tactile extinction: Distinguishing between sensorimotor and motor asymmetries in rats with unilateral nigrostriatal damage , 1982, Pharmacology Biochemistry and Behavior.

[6]  L. Pitts,et al.  Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. , 1986, Stroke.

[7]  P. Weinstein,et al.  Reversible middle cerebral artery occlusion without craniectomy in rats. , 1989, Stroke.

[8]  Aspey,et al.  Middle cerebral artery occlusion in the rat: consistent protocol for a model of stroke , 1998, Neuropathology and applied neurobiology.

[9]  F Yonemori,et al.  Spatial Cognitive Performance after Chronic Focal Cerebral Ischemia in Rats , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[10]  R A Swanson,et al.  A Semiautomated Method for Measuring Brain Infarct Volume , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[11]  W. Frey,et al.  Intranasal administration of insulin-like growth factor-I bypasses the blood–brain barrier and protects against focal cerebral ischemic damage , 2001, Journal of the Neurological Sciences.

[12]  M. Mattson,et al.  IGF-I and IGF-II protect cultured hippocampal and septal neurons against calcium-mediated hypoglycemic damage , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[13]  Timothy Schallert,et al.  Seizures and recovery from experimental brain damage , 1988, Experimental Neurology.

[14]  P. Gluckman,et al.  A role for IGF-1 in the rescue of CNS neurons following hypoxic-ischemic injury. , 1992, Biochemical and biophysical research communications.

[15]  M. Ross,et al.  Aminoguanidine ameliorates and L-arginine worsens brain damage from intraluminal middle cerebral artery occlusion. , 1996, Stroke.